Table 2 Expression of GAGE, NY-ESO-1 and SP17 in human NSCLC
Tumor expression of antigen | Histotype | All NSCLC specimens (n = 169) | ||
|---|---|---|---|---|
Adenocarcinoma (n = 81) | Squamous cell carcinoma (n = 88)* | p-value | ||
GAGE | 15 (18.5%) | 29 (33.0%) | 0.19 | 44 (26.0%) |
>1% - ≤ 10% | 5 (6.2%) | 5 (5.7%) | ||
>10% - ≤ 50% | 2 (2.5%) | 4 (4.6%) | ||
>50% | 8 (9.9%) | 20 (22.7%) | 0.02 | |
NY-ESO-1 | 8 (9.9%) | 12 (13.6%) | 0.49 | 20 (11.8%) |
>1% - ≤ 10% | 2 (2,5%) | 1 (1.1%) | ||
>10% - ≤ 50% | 2 (2.5%) | 1 (1.1%) | ||
>50% | 4 (4.9%) | 10 (11.4%) | 0.13 | |
SP17 | 4 (4.9%) | 4 (4.6%) | 0.76 | 8 (4.7%) |
>1% - ≤ 10% | 4 (4.9%) | 4 (4.6%) | ||
>10% - ≤ 50% | 0 | 0 | ||
>50% | 0 | 0 | ||